What is New in Clinical Kidney and Liver Transplantation
Magdalena DurlikAnn Transplant 2005; 10(3): 46-46 :: ID: 496211
Abstract
A current challenge in renal transplantation is to develop immunosuppressive regimens without adverse effects including nephrotoxicity and cardiovascular risk. A significant number of presentations were focused on steroid or caliceurin inhibitor avoidance regimens. New immunosuppressive agents compensated steroid or CNI avoidance have become available. A novel strategy includes minimising of maintenance immunosuppression through the
aggressive use depletion induction therapy.
Keywords: Liver
In Press
Original article
Fundamental Strategies and Technical Perspectives in Bile Duct Anastomosis for Living Donor Liver Transplan...Ann Transplant In Press; DOI: 10.12659/AOT.953761
Clinical Research
Retrospective Study of Implementation and Outcomes of a Non-Cryopreserved Autologous Hematopoietic Stem Cel...Ann Transplant In Press; DOI: 10.12659/AOT.954230
Clinical Research
Prognostic Prediction in Living Donor Liver Transplantation Recipients With Complete Pathological Response ...Ann Transplant In Press; DOI: 10.12659/AOT.954574
Most Viewed Current Articles
24 Aug 2021 : Review article 21,978
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 18,247
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
22 Nov 2022 : Original article 16,856
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
05 Apr 2022 : Original article 16,762
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604